468 results about "Fatty liver" patented technology

The invention belongs to the field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating liver depression and spleen deficiency syndrome metabolism-related fatty liver disease, which is prepared from the following raw materials in parts by weight: 8 to 10 parts of ginseng, 10 to 15 parts of radix bupleuri, 10 to 15 parts of radix curcumae, 6 to 9 parts of ginger processed pinellia, 6 to 10 parts of fructus amomi, 10 to 15 parts of rhizoma atractylodis, 10 to 15 parts of poria cocos, 10 to 15 parts of semen hoveniae, 10 to 15 parts of radix rehmanniae, 8 to 10 parts of rhizoma polygoni cuspidati and 6 to 9 parts of lignum dalbergiae odoriferae. The traditional Chinese medicine composition is used for treating the metabolism-related fatty liver diseases from the aspects of liver depression, spleen deficiency and phlegm-blood stasis, starts from the core pathological chain of liver depression, spleen deficiency, phlegm-dampness and blood stasis, has the functions of soothing the liver, tonifying the spleen, resolving dampness, reducing fat and promoting blood circulation to remove meridian obstruction, and is particularly suitable for patients with liver depression, spleen deficiency and metabolism-related fatty liver diseases. Clinical tests prove that the traditional Chinese medicine composition has a good treatment effect on patients with liver depression and spleen deficiency syndrome metabolism-related fatty liver diseases, the total effective rate reaches 94% or above, and the traditional Chinese medicine composition is mild in medicine property, good in safety, stable in curative effect, not prone to relapse and suitable for being taken for a long time.

The invention discloses a multi-classification auxiliary prediction method and system for metabolism-related fatty liver diseases, electronic equipment and a storage medium, belongs to the field of medical data processing, and is used for solving the problem that a traditional MAFLD binary prediction model cannot fully reflect continuous pedigree of disease severity. The method comprises the following steps: acquiring clinical data related to classification prediction of metabolism-related fatty liver diseases; performing label coding, missing value filling and feature screening on the clinical data; and inputting the screened features into a TabNet classification model optimized by a particle swarm algorithm, and outputting a risk classification result of the metabolism-related fatty liver disease. According to the method, the severity of the fatty liver can be more accurately evaluated, the liver health condition of a patient is comprehensively reflected, and more accurate treatment guidance is provided for clinical diagnosis.

The present invention is directed to substituted 1-(1H-imidazol-1-yl)-3-methyl-2- phenylbutan-2-ol and 1-cyclopentyl-2-(1H-imidazol-1-yl)-1-phenylethan-1-ol compounds useful as agonists of 8-oxo-guanine DNA glycosylase (OGG1) in humans, as well as pharmaceutical compositions comprising them and methods of their use in treating diseases, including metabolic syndrome, obesity, fatty liver disease, dyslipidemia, insulin resistance, neurodegenerative disorders and cancers.

The invention relates to the technical field of liver disease prediction, in particular to a metabolism-related fatty liver disease intelligent prediction method and system and a storage medium. The method comprises the following steps: collecting multi-source data, respectively obtaining basic demographic information, laboratory indexes and prediction indexes, and extracting quantitative and qualitative tongue picture parameters; performing variable screening on the tongue picture parameters and the clinical indexes, and determining key prediction variables; obtaining a key variable value according to the key prediction variable, obtaining a prediction result of the occurrence risk of the metabolism-related fatty liver disease, and outputting the prediction result; the system comprises a multi-source data acquisition module, a variable screening module and a prediction result acquisition module. By means of the mode, the intelligent tongue picture parameters and the clinical indexes are fused, and the effect of early prediction of the metabolism-related fatty liver diseases is achieved.

The invention belongs to the technical field of biological pharmacy, and provides an application of jonquil glucoside in preparation of a medicine for treating a metabolism-related fatty liver disease, and the application is that the jonquil glucoside is applied to preparation of the medicine for treating the metabolism-related fatty liver disease. The treatment effect of the jonquil glycoside on MASLD is evaluated by adopting a method for establishing a fatty liver model through induction of HFD high-fat, high-fructose and high-cholesterol feed. Results show that the jonquil glucoside can reduce the liver weight by inhibiting weight gain, reduce the content of TC and TG in serum, improve the conditions of liver inflammation and fat change, reduce the oxidative stress level of liver tissue and restore SIRT1 protein expression of the liver tissue to achieve the purpose of treating MASLD.

The invention belongs to the technical field of biological medicines, and particularly relates to a traditional Chinese medicine composition for treating metabolism-related fatty liver diseases and a preparation method thereof. The technical problem to be solved by the invention is to provide a new choice for treating metabolism-related fatty liver diseases. According to the technical scheme, the traditional Chinese medicine composition for treating the metabolism-related fatty liver disease is prepared from the following components: radix paeoniae rubra, cyrtomium fortunei, curcuma zedoary, sculellaria barbata, herba epimedii, fingered citron, semen cassiae and herba artemisiae scopariae. The invention is mainly used for providing a new choice for treating the metabolism-related fatty liver disease, and has a wide application prospect.

The invention relates to a preparation method of a silymarin and pueraria isoflavone composite reagent. The preparation method comprises the following steps: S1, extracting silybin; s2, soaking the roots and stems of the kudzuvine roots; s3, extracting a radix puerariae isoflavone stock solution; s4, concentrating the radix puerariae isoflavone stock solution; s5, extracting a pueraria isoflavone concentrated solution; s6, mixing and granulating; and S7, tabletting and coating to obtain the flaky silymarin and pueraria isoflavone composite reagent. According to the prepared silymarin and pueraria isoflavone composite reagent, the silymarin dry powder and the pueraria isoflavone extract serve as core components, the silymarin dry powder can enhance liver detoxification and repair liver cells, the pueraria isoflavone extract can accelerate alcohol metabolism, and the silymarin dry powder and the pueraria isoflavone extract have a remarkable improvement effect on fatty liver, alcoholic liver and the like under the synergistic effect.

The present invention belongs to the technical field of drug or functional food application. The present invention discloses a compound of the following structural formula and the use of the compound in preparing a drug for treating fatty liver disease or a functional food for alleviating fatty liver disease. Also disclosed is Eurotium cristatum ( Eurotium cristatum )SXHBTBU1934 and a method for preparing the compound.

The invention discloses a multi-classification risk prediction method and system for liver diseases based on machine learning, and relates to the technical field of biomedicine, and the method comprises the following steps: collecting fatty liver disease diagnosis results and biochemical indexes of a subject to form a training sample set, the method comprises the following steps: screening out biochemical indexes significantly related to fatty liver diseases through single-factor regression analysis, determining potential risk factors, carrying out multicollinearity test on the factors, screening out risk factors, constructing a plurality of machine learning classification models for training, and selecting a model with the best performance as a reference model. The contribution degree of each important risk factor is evaluated and sorted, classification significant factors are determined, the significant factors serve as classification metadata, a plurality of judgment models are trained, input factors are dynamically selected according to contribution values, and finally a fatty liver disease degree classification result is output, so that complex conditions under different sample features and clinical backgrounds are better handled; and the accuracy of prediction results is improved.

The invention provides a nano-drug delivery system for treating fatty liver based on liposome, exosome and metal organic framework synergistic targeting and a preparation method of the nano-drug delivery system, and relates to the technical field of novel nano-material preparation, the nano-drug delivery system comprises liposome, mesenchymal stem cell exosome and metal organic framework nanoparticles; the liposome is used as a carrier and entraps the metal organic framework nano-particles, the mesenchymal stem cell exosome and the miR-204-3p which have a slow release characteristic. By integrating the advantages of the liposome, the exosome and the metal organic framework, the synergistic treatment of the MASLD is realized. According to the system, lipidosome is adopted as an intelligent carrier, MOF nanoparticles and mesenchymal stem cell exosomes with slow release characteristics are entrapped, and therapeutic miR-204-3p is loaded at the same time. The MOF material has functions of drug controlled release and active oxygen removal, and synergistically exerts anti-oxidation, anti-inflammatory and anti-fibrosis effects with the exosome and miRNA. The system has a pH response characteristic, and can intelligently release drugs in an acidic microenvironment of an MASLD focus to realize targeted treatment of the liver.

The invention discloses a composition capable of quickly dispelling the effects of alcohol and relieving moderate and mild fatty liver and application of the composition, and particularly relates to the technical field of health care products. The composition comprises the silybum marianum extract, the schisandra chinensis extract, the globe artichoke extract and the 1, 6-fructose diphosphate and cyclodextrin-clathrated silybum marianum extract as raw materials, on one hand, the bioavailability of the product is improved, the taste of the product is better, and the taste of the clathrated product is improved due to the fact that silybin is very bitter and cyclodextrin has a shielding property; and on the other hand, the FDP and the three plant extracts have a synergistic effect, and the combined composition can achieve the effects of quickly dispelling the effects of alcohol and relieving moderate and mild fatty liver.

The invention relates to a preparation method and application of a medicine-food homologous compound with weight-losing and lipid-lowering effects. According to the present invention, the weight of the obese mouse can be reduced by 23.23% at most, the serum total cholesterol is reduced, the leptin secretion is reduced, AST (aspartate transaminase) and ALT (alanine transaminase) have no significant difference compared to the model mouse, the volume of epididymal fat and inguinal fat cells is reduced, the number of cells in unit area is significantly increased, the fatty liver sample is relieved, the TMEM26 gene expression in the epididymal fat is significantly increased, and the weight of the obese mouse can be significantly reduced; the expression quantity of the UCP1 gene in brown fat is obviously increased. The traditional Chinese medicine composition adopts medicinal and edible substances as raw materials, is widely applicable to people, is more suitable for prevention and treatment of chronic diseases, is safe and effective, and causes little damage to liver and kidney after long-term use.

The present application relates to the field of medicine, and specifically to a GLP-1 analog fusion protein and its application. The GLP-1 analog fusion protein is obtained by fusing GLP-1 to the N-terminus of the IgG4 heavy chain constant region and the light chain constant region. The results of the study showed that the GLP-1 analog fusion protein of the present application has a significant effect on reducing the weight of mice. The volume and weight of the mouse liver decreased, and the NAS score and hepatic steatosis were significantly improved. Therefore, the present invention can be applied to drugs or products for weight loss or the treatment of fatty liver.

The present invention relates to the use of an ROR inverse agonist or a pharmaceutically acceptable salt thereof for the preparation of a medicament for modulating ROR in a patient and / or for controlling autoimmune diseases and antibody-mediated rejection in a patient. The ROR-mediated diseases or autoimmune diseases include HIV, cancer, celiac disease, type 1 diabetes, Graves' disease (Graves' disease), inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease (Crohn's disease), cardiovascular disease, inflammatory disease, nervous system disorders, multiple sclerosis, and the like. Acute respiratory distress syndrome and arteriosclerosis.

Methods and compositions for treating fatty liver and viral infections are provided. Aspects of the methods includes administering to a subject in need thereof an effective amount of a KxL motif binding agent, e.g., A27, to treat the subject. Also provided are compositions for use in practicing embodiments of the methods.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition with an effect of preventing and treating alcoholic liver injury as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines: radix puerariae, turmeric, ginseng, hovenia dulcis thunb, white hyacinth bean, raw oyster shell, poria cocos, raw hawthorn, biond magnolia flower, juncus effuses and albizia flower. The traditional Chinese medicine composition has the effects of soothing liver and harmonizing stomach, dispelling alcohol effect and enlivening spleen, and reinforcing qi and nourishing blood. Experimental results show that the traditional Chinese medicine composition has a good treatment effect on acute alcoholic liver injury and chronic alcoholic fatty liver, and can effectively improve the symptoms of chest rib swelling pain, reduced appetite, anorexia, abdominal distension, hiccup, belching, borborygmus and qi and loose stool caused by liver-stomach disharmony and spleen deficiency and dampness of alcoholic liver injury patients; therefore, the method has good development and utilization prospects.

The application discloses a construction method of a fat-targeted gene therapy vector. The method comprises the following steps: obtaining a fat tissue-specific promoter sequence; obtaining a shRNA coding sequence targeting a Tks4 gene; cloning the promoter sequence and the shRNA coding sequence into an adeno-associated virus vector skeleton to construct a recombinant expression vector; and co-transfecting the recombinant expression vector and an auxiliary plasmid into a packaging cell to package and purify a recombinant adeno-associated virus particle. The vector constructed by the application adopts an adiponectin promoter to drive the expression of miR30-shRNA targeting the Tks4, and can be specifically expressed in fat tissues and livers after being injected through a tail vein, significantly inhibits fat cell hypertrophy and systemic fat accumulation induced by a high-fat diet, reduces the serum cholesterol level, does not cause an immune inflammatory reaction, does not affect sugar metabolism, and is not expressed in non-target tissues. The application provides a safe and efficient new strategy for the gene therapy of obesity, hyperlipidemia, fatty liver and related metabolic diseases.

The invention belongs to traditional Chinese medicine formula granules, and particularly relates to a preparation process of phlegm-eliminating and blood-activating granules and application of the phlegm-eliminating and blood-activating granules in metabolism-related fatty liver diseases. The granule comprises gynostemma pentaphylla and raw hawthorn which are used as monarch drugs, raw bighead atractylodes rhizome, rhodiola rosea and turmeric which are used as ministerial drugs, and auxiliary materials for preparing the granule. The granules with the formula for eliminating phlegm and activating blood, which are researched and developed by the invention, have the characteristics of stable property, convenience in transportation, carrying, storage and use and the like. The preparation technology is high in production efficiency and has good economic value, and the prepared granules can effectively exert the pesticide effect.

The present invention discloses a golden chrysanthemum flavonoid glycoside derived from golden chrysanthemum, wherein the golden chrysanthemum flavonoid glycoside is apigenin 7-O-(6"-O-malonyl)-β-D-glucoside derived from golden chrysanthemum. The present invention separates and purifies apigenin 7-O-(6"-O-malonyl)-β-D-glucoside from golden chrysanthemum for the first time, completes the first synthesis through a 5-step synthesis process with a total yield of 2.7%, and discovers for the first time that the compound has activity in improving hyperlipidemia and fatty liver in vitro and in vivo. Therefore, the compound can be used in the preparation of products for treating related diseases such as hyperlipidemia and fatty liver.

The invention belongs to the technical field of biological medicine, and discloses a pharmaceutical composition for treating metabolic diseases, a preparation method and application, and the pharmaceutical composition comprises edaravone or pharmaceutically acceptable salts thereof and dextroborneol. The weight ratio of the edaravone to the dextroborneol is (10: 1)-(1: 1). The invention finds that the combination of edaravone and dextroborneol shows remarkable curative effects in the aspects of improving cognitive function, reducing blood fat, relieving fatty liver and recovering cardiac function and / or overall metabolic homeostasis; meanwhile, the pharmaceutical composition disclosed by the invention has a remarkable comprehensive treatment effect on metabolic diseases or complications (such as metabolic syndrome) of the metabolic diseases and / or vascular cognitive impairment complicated with the metabolic syndrome.

The present invention relates to methods for treating overweight or obese in individuals in need thereof, and / or individuals with fatty liver disease or diabetes. In particular, the present invention relates to a method of treating obesity, fatty liver disease or diabetes in an individual in need thereof, the method comprising administering a SIK-3 inhibitor and a metabolic modulator to the individual.

The present invention relates to the preventive, alleviative, or therapeutic effects of an extract of Cucumis melo var. makuwa leaves, particularly an alcoholic extract of Cucumis melo var. makuwa leaves, on fatty liver disease associated with metabolic dysfunction. The extract of Cucumis melo var. makuwa leaves according to the present invention can reduce liver weight and the accumulation of fat in liver tissue, and can significantly inhibit ALT activity in the blood, and thus can provide an effective fatty liver prevention, alleviation, or treatment effect. In addition, the extract of Cucumis melo var. makuwa leaves according to the present invention has a high yield of about 21% and thus may be highly economical as an excellent material for preventing, alleviating or treating fatty liver disease.

The invention relates to an obesity risk prediction system based on multi-modal iconography, and relates to the field of electrical digital data processing, and the system comprises a layer-by-layer construction device which is used for obtaining an obesity risk prediction model; and the risk prediction device is used for intelligently predicting the fatty liver grade and the easily fat food name of the to-be-analyzed person according to the liver QCT picture information of the to-be-analyzed person and the fMRI imaging data of the obesity-related brain region by adopting an obesity risk prediction model. The invention also relates to an obesity risk prediction method based on multi-modal iconography. According to the invention, the technical problems of insufficient obesity risk parameter analysis precision and single parameter type of the to-be-analyzed person are solved; synchronous intelligent prediction of two obesity risk parameters, namely the fatty liver grade and the easy-to-fat food name, of a person to be analyzed can be realized based on multiple items of basic data screened in a targeted manner by adopting an obesity risk prediction model based on multi-modal iconography of a customized structure, so that the technical problem is solved.

The invention discloses a 3-hydroxyisovaleric acid and guaiacol composition and application of the 3-hydroxyisovaleric acid and guaiacol composition in preparation of a medicine for treating or preventing glucose metabolism disorder. The invention provides a strategy for treating metabolic diseases by combining 3-hydroxyisovaleric acid and guaiacol for the first time. It is found that combination of the two has a significant synergistic effect, and combination of low doses is superior to single use of high doses. Systematic animal experiments prove that the traditional Chinese medicine composition has a remarkable effect of improving blood sugar, insulin resistance and fatty liver.

The utility model provides a fatty liver sample storage device, which relates to the technical field of storage devices, and comprises a refrigeration box body, a plurality of clapboards are equidistantly arranged in the refrigeration box body from the right upper part to the lower part, a plurality of fixing mechanisms are equidistantly arranged at the top ends of the clapboards, and each fixing mechanism comprises a base. The base is fixedly installed at the top end of the partition plate, a buffering assembly is installed in the base, a fixing base is fixedly connected to the back face of the base, a pressing assembly is arranged in the fixing base, and clamping assemblies are symmetrically installed in the fixing base and located on the left side and the right side of the pressing assembly; according to the fatty liver sample storage device, the base, the buffering assembly, the fixing base, the pressing assembly and the clamping assembly are used in cooperation, test tubes loaded with fatty liver samples can be stably placed, meanwhile, rapid placing and taking work can be achieved, compared with a traditional storage device, the placing and taking stability is greatly improved, and practicability is effectively improved.

The invention discloses liquiritigenin and isoliquiritigenin produced by directionally converting liquiritin and isoliquiritigenin through lactobacillus plantarum CCFM1275 and application of the liquiritigenin and the isoliquiritigenin. Researches show that the lactobacillus plantarum CCFM1275 can grow in a fermentation base material rich in a licorice extract, and liquiritin and isoliquiritin in licorice can be converted into liquiritigenin and isoliquiritigenin respectively, so that utilization of active ingredients of liquiritin and isoliquiritigenin by an organism is facilitated, and the effect of the licorice extract is improved. Compared with the licorice root extract, the fermented licorice root postbiotics obtained by fermenting and converting the licorice root extract through the lactobacillus plantarum CCFM1275 can further improve the effects of the licorice root extract in the aspects of reducing liver lipid accumulation, lowering lipid and resisting aging, can be used for preparing products with the effects of preventing and / or treating fatty liver and obesity and / or resisting aging, and has a huge application prospect.

The invention relates to the field of medicines, and discloses a novel human PYY analogue, and compared with a PYY3-36 natural sequence, the novel human PYY analogue has a remarkable effect on improving metabolic diseases such as obesity, diabetes and fatty liver and emotional diseases such as anxiety disorder and depression.

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and / or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and / or prophylaxis of diseases, especially for treatment and / or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

This invention discloses a gRNA combination and its application in the preparation of drugs for the prevention of metabolic-associated fatty liver disease (MASLD). The gRNA combination, when mixed with Cas9 protein, yields an RNP complex, which, when microinjected into mouse zygotes, can breed a stable and heritable mouse strain with TMEM68 gene knockout. Combining lipidomics, transcriptomics, and primary hepatocyte functional verification, the core regulatory role of TMEM68 in hepatic lipid metabolism is revealed for the first time systematically. Experiments demonstrate that TMEM68 deficiency significantly reduces the storage of triglycerides (TAG) in the liver and hepatocytes, decreases lipid droplet formation, and reshapes the metabolic homeostasis of various lipids such as glycerophospholipids, cholesterol esters, and bile acids. Therefore, the gRNA combination of this invention, or the RNP complex obtained by mixing the gRNA combination with Cas9 protein, can be used to prepare drugs for the prevention of MASLD, providing a novel intervention strategy for MASLD prevention with broad application prospects.

The application belongs to the field of genetic engineering and biosynthesis, and particularly relates to biosynthesis of a class of diterpenoids. The application provides genes having a key role in the formation of a 5-8-5 tricyclic mother nucleus and a five-membered heterocyclic ring in biosynthesis of the class of diterpenoids, which are respectively named as PrcA and PrcB and polypeptides encoded by the genes, expression of PrcA and PrcB is carried out through a heterologous expression system of Aspergillus oryzae, and five diterpenoids with novel structures and anti-metabolic related fatty liver disease activity are obtained. The application provides application of the polypeptides in biosynthesis of the class of diterpenoids, and enriches a diterpenoid library, thereby providing lead compound resources for discovering new anti-metabolic related fatty liver disease medicinal raw materials.